* “tiefe Invasion“ ist definiert als Invasion jenseits des subkutanen Fettgewebes oder >6 mm (gemessen vom Stratum granulosum der benachbarten Epidermis bis zur Basis des Tumors). Eine perineurale Invasion als Kriterium für T3 ist definiert als klinische oder radiologische Beteiligung benannter Nerven ohne Beteiligung der Foramina oder der Schädelbasis.
Primary tumor cannot be assessed
No evidence of primary tumor
Carcinoma in situ
Tumor 2 cm or less in greatest dimension with less than two high-risk features**
Tumor greater than 2 cm in greatest dimension or Tumor any size with two or more high-risk features**
Tumor with invasion of maxilla, mandible, orbit, or temporal bone
Tumor with invasion of skeleton (axial or appendicular) or perineural invasion of skull base
*Excludes sSCC of the eyelid (see carcinoma of the eyelid)
**See high risk features tab
Regional lymph nodes cannot be assessed
No regional lymph node metastases
Metastasis in a single ipsilateral lymph node, 3 cm or less in greatest dimension
Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none more than 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes; none more than 6 cm in greatest dimension
Metastasis in a single ipsilateral lymph node, more than 3 cm but not more than 6 cm in greatest dimension
Metastasis in multiple ipsilateral lymph node, none more than 6 cm in greatest dimension
Metastasis in bilateral or contralateral lymph nodes, none more than 6 cm in greatest dimension
Metastasis in a lymph node, more than 6 cm in greatest dimension
No distant metastases
Distant metastases
Stadium 0
Tis
N0
M0
Stadium I
T1
Stadium II
T2
Stadium III
T3
T1, T2, T3
N1
Stadium IV
N2, N3
T4
Jedes N
Jedes T
M1
>2 mm thickness
Clark level ≥ IV
Perineural invasion
Primary site ear
Primary site hair-bearing lip
Poorly differentiated or undifferentiated
Patients with primary cSCC or other cutaneous carcinomas with no evidence (clinical, radiologic, or pathologic) of regional or distant metastases are divided into two stages: Stage I for tumors measuring ≤ 2 cm in size and Stage II for those that are greater than 2 cm in size. In instances where there is clinical concern for extension of tumor into bone and radiologic evaluation has been performed (and is negative), these data may be included to support the Stage I vs. II designation. Tumors that are ≤ 2 cm in size can be upstaged to Stage II if they contain two or more high-risk features. Stage III patients are those with (1) clinical, histologic, or radiologic evidence of one solitary node measuring ≤ 3 cm in size or (2) Tumor extension into bone: maxilla, mandible, orbit, or temporal bone. Stage IV patients are those with (1) tumor with direct or perineural invasion of skull base or axial skeleton, (2) ≥ 2 lymph nodes or (3) single or multiple lymph nodes measuring >3 cm in size or (4) distant metastasis.